View in EDS HTML Full Text PDF Full Text

Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.

Saved in:
Bibliographic Details
Title: Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
Authors: Fisher SS; RTI International, Durham, North Carolina, United States of America., Lindaas A; Acumen LLC, Burlingame, California, United States of America., Muthuri SG; IBM Consulting, Bethesda, Maryland, United States of America., Lloyd PC; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Gruber JF; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Richey MM; RTI Health Solutions, Durham, North Carolina, United States of America., Lyu H; Acumen LLC, Burlingame, California, United States of America., Cheng AS; Acumen LLC, Burlingame, California, United States of America., Kowarski LS; IBM Consulting, Bethesda, Maryland, United States of America., McKillop MM; IBM Consulting, Bethesda, Maryland, United States of America., Bui C; RTI Health Solutions, Durham, North Carolina, United States of America., Clarke TC; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Beers J; IBM Consulting, Bethesda, Maryland, United States of America., Burrell T; IBM Consulting, Bethesda, Maryland, United States of America., Duenas PF; Acumen LLC, Burlingame, California, United States of America., Chen Y; Acumen LLC, Burlingame, California, United States of America., Sheng M; IBM Consulting, Bethesda, Maryland, United States of America., Forshee RA; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Anderson SA; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Chillarige Y; Acumen LLC, Burlingame, California, United States of America., Anthony MS; RTI Health Solutions, Durham, North Carolina, United States of America., Shoaibi A; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America., Layton JB; RTI Health Solutions, Durham, North Carolina, United States of America.
Source: PloS one [PLoS One] 2025 Nov 24; Vol. 20 (11), pp. e0333704. Date of Electronic Publication: 2025 Nov 24 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41284649
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fisher+SS%22">Fisher SS</searchLink>; RTI International, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Lindaas+A%22">Lindaas A</searchLink>; Acumen LLC, Burlingame, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Muthuri+SG%22">Muthuri SG</searchLink>; IBM Consulting, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Lloyd+PC%22">Lloyd PC</searchLink>; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Gruber+JF%22">Gruber JF</searchLink>; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Richey+MM%22">Richey MM</searchLink>; RTI Health Solutions, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Lyu+H%22">Lyu H</searchLink>; Acumen LLC, Burlingame, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Cheng+AS%22">Cheng AS</searchLink>; Acumen LLC, Burlingame, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Kowarski+LS%22">Kowarski LS</searchLink>; IBM Consulting, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22McKillop+MM%22">McKillop MM</searchLink>; IBM Consulting, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Bui+C%22">Bui C</searchLink>; RTI Health Solutions, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Clarke+TC%22">Clarke TC</searchLink>; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Beers+J%22">Beers J</searchLink>; IBM Consulting, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Burrell+T%22">Burrell T</searchLink>; IBM Consulting, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Duenas+PF%22">Duenas PF</searchLink>; Acumen LLC, Burlingame, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Acumen LLC, Burlingame, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Sheng+M%22">Sheng M</searchLink>; IBM Consulting, Bethesda, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Forshee+RA%22">Forshee RA</searchLink>; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Anderson+SA%22">Anderson SA</searchLink>; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Chillarige+Y%22">Chillarige Y</searchLink>; Acumen LLC, Burlingame, California, United States of America.<br /><searchLink fieldCode="AU" term="%22Anthony+MS%22">Anthony MS</searchLink>; RTI Health Solutions, Durham, North Carolina, United States of America.<br /><searchLink fieldCode="AU" term="%22Shoaibi+A%22">Shoaibi A</searchLink>; United States of America Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, Maryland, United States of America.<br /><searchLink fieldCode="AU" term="%22Layton+JB%22">Layton JB</searchLink>; RTI Health Solutions, Durham, North Carolina, United States of America.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101285081%22">PloS one</searchLink> [PLoS One] 2025 Nov 24; Vol. 20 (11), pp. e0333704. <i>Date of Electronic Publication: </i>2025 Nov 24 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Public+Library+of+Science%22">Public Library of Science </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101285081 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1932-6203 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219326203%22">19326203 </searchLink><i>NLM ISO Abbreviation: </i>PLoS One <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41284649
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1371/journal.pone.0333704
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e0333704
    Titles:
      – TitleFull: Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fisher SS
      – PersonEntity:
          Name:
            NameFull: Lindaas A
      – PersonEntity:
          Name:
            NameFull: Muthuri SG
      – PersonEntity:
          Name:
            NameFull: Lloyd PC
      – PersonEntity:
          Name:
            NameFull: Gruber JF
      – PersonEntity:
          Name:
            NameFull: Richey MM
      – PersonEntity:
          Name:
            NameFull: Lyu H
      – PersonEntity:
          Name:
            NameFull: Cheng AS
      – PersonEntity:
          Name:
            NameFull: Kowarski LS
      – PersonEntity:
          Name:
            NameFull: McKillop MM
      – PersonEntity:
          Name:
            NameFull: Bui C
      – PersonEntity:
          Name:
            NameFull: Clarke TC
      – PersonEntity:
          Name:
            NameFull: Beers J
      – PersonEntity:
          Name:
            NameFull: Burrell T
      – PersonEntity:
          Name:
            NameFull: Duenas PF
      – PersonEntity:
          Name:
            NameFull: Chen Y
      – PersonEntity:
          Name:
            NameFull: Sheng M
      – PersonEntity:
          Name:
            NameFull: Forshee RA
      – PersonEntity:
          Name:
            NameFull: Anderson SA
      – PersonEntity:
          Name:
            NameFull: Chillarige Y
      – PersonEntity:
          Name:
            NameFull: Anthony MS
      – PersonEntity:
          Name:
            NameFull: Shoaibi A
      – PersonEntity:
          Name:
            NameFull: Layton JB
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 24
              M: 11
              Text: 2025 Nov 24
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1932-6203
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: PloS one
              Type: main
ResultId 1